|
1.
|
Parl FF, Schmidt BP, Dupont WD and Wagner
RK: Prognostic significance of estrogen receptor status in breast
cancer in relation to tumor stage, axillary node metastasis, and
histopathologic grading. Cancer. 54:2237–2242. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Doane AS, Danso M, Lal P, Donaton M, Zhang
L, Hudis C and Gerald WL: An estrogen receptor-negative breast
cancer subset characterized by a hormonally regulated
transcriptional program and response to androgen. Oncogene.
25:3994–4008. 2006. View Article : Google Scholar
|
|
3.
|
Carey LA, Dees EC, Sawyer L, et al: The
triple negative paradox: primary tumor chemosensitivity of breast
cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Sorlie T, Perou CM, Tibshirani R, et al:
Gene expression patterns of breast carcinomas distinguish tumor
subclasses with clinical implications. Proc Natl Acad Sci USA.
98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Kaplan HG and Malmgren JA: Impact of
triple negative phenotype on breast cancer prognosis. Breast J.
14:456–463. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Anand P, Thomas Sherin G, Kunnumakkara
Ajaikumar B, et al: Biological activities of curcumin and its
analogues (Congeners) made by man and Mother Nature. Biochem
Pharmacol. 76:1590–1611. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Cheng A-L, Hsu C-H, Lin J-K, et al: Phase
I clinical trial of curcumin, a chemopreventive agent, in patients
with high-risk or pre-malignant lesions. Anticancer Res.
21:2895–2900. 2001.PubMed/NCBI
|
|
8.
|
Inano H, Onoda M, Inafuku N, et al:
Chemoprevention by curcumin during the promotion stage of
tumorigenesis of mammary gland in rats irradiated with gamma-rays.
Carcinogenesis. 20:1011–1018. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Pereira MA, Grubbs CJ, Barnes LH, et al:
Effects of the phytochemicals, curcumin and quercetin, upon
azoxymethane-induced colon cancer and
7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats.
Carcinogenesis. 17:1305–1311. 1996.PubMed/NCBI
|
|
10.
|
Schaaf C, Shan B, Buchfelder M, et al:
Curcumin acts as anti-tumorigenic and hormone-suppressive agent in
murine and human pituitary tumour cells in vitro and in vivo.
Endocr Relat Cancer. 16:1339–1350. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Singletary K, MacDonald C, Wallig M and
Fisher C: Inhibition of 7,12-dimethylbenz[a]anthracene
(DMBA)-induced mammary tumorigenesis and DMBA-DNA adduct formation
by curcumin. Cancer Lett. 103:137–141. 1996.
|
|
12.
|
Chiu T-L and Su C-C: Curcumin inhibits
proliferation and migration by increasing the Bax to Bcl-2 ratio
and decreasing NF-κBp65 expression in breast cancer MDA-MB-231
cells. Int J Mol Med. 23:469–475. 2009.PubMed/NCBI
|
|
13.
|
Kang HJ, Lee SH, Price JE and Kim LS:
Curcumin suppresses the paclitaxel-induced nuclear factor-κB in
breast cancer cells and potentiates the growth inhibitory effect of
paclitaxel in a breast cancer nude mice model. Breast J.
15:223–229. 2009.
|
|
14.
|
Liu Q, Loo WTY, Sze SCW and Tong Y:
Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483
breast cancer cells mediated by down-regulation of NFκB, cyclinD
and MMP-1 transcription. Phytomed. 16:916–922. 2009.PubMed/NCBI
|
|
15.
|
Prasad CP, Rath G, Mathur S, Bhatnagar D
and Ralhan R: Potent growth suppressive activity of curcumin in
human breast cancer cells: Modulation of Wnt/beta-catenin
signaling. Chem Biol Interact. 181:263–271. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Rowe DL, Ozbay T, O’Regan RM and Nahta R:
Modulation of the BRCA1 protein and induction of apoptosis in
triple negative breast cancer cell lines by the polyphenolic
compound curcumin. Breast Cancer Basic Clin Res. 3:61–75.
2009.PubMed/NCBI
|
|
17.
|
Somers-Edgar TJ, Scandlyn MJ, Stuart EC,
Le Nedelec MJ, Valentine SP and Rosengren RJ: The combination of
epigallocatechin gallate and curcumin suppresses ERalpha-breast
cancer cell growth in vitro and in vivo. Int J Cancer.
122:1966–1971. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Wu X and Wu K: Antiproliferative effect of
curcumin on human breast cancer of MCF-7 cells. Di-San Junyi Daxue
Xuebao. 28:1870–1872. 2006.
|
|
19.
|
Liang G, Shao L, Wang Y, et al:
Exploration and synthesis of curcumin analogues with improved
structural stability both in vitro and in vivo as cytotoxic agents.
Bioorg Med Chem. 17:2623–2631. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Markaverich BM, Schauweker TH, Gregory RR,
Varma M, Kittrell FS, Medina D and Varma RS: Nuclear type II sites
and malignant cell proliferation: inhibition by
2,6-bis-benzylidenecyclohexanones. Cancer Res. 52:2482–2488.
1992.PubMed/NCBI
|
|
21.
|
Adams BK, Ferstl EM, Davis MC, et al:
Synthesis and biological evaluation of novel curcumin analogs as
anti-cancer and anti-angiogenesis agents. Bioorg Med Chem.
12:3871–3883. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Adams Brian K, Cai J, Armstrong J, et al:
EF24, a novel synthetic curcumin analog, induces apoptosis in
cancer cells via a redox-dependent mechanism. Anticancer Drugs.
16:263–275. 2005.PubMed/NCBI
|
|
23.
|
Yadav B, Taurin S, Rosengren RJ,
Schumacher M, Diederich M, Somers-Edgar TJ and Larsen L: Synthesis
and cytotoxic potential of heterocyclic cyclohexanone analogues of
curcumin. Bioorg Med Chem. 18:6701–6707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Skehan P, Storeng R, Scudiero D, et al:
New colorimetric cytotoxicity assay for anti-cancer drug screening.
J Natl Cancer Inst. 82:1107–1112. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Somers-Edgar TJ, Taurin S, Larsen L,
Chandramouli A, Nelson MA and Rosengren RJ: Mechanisms for the
activity of heterocyclic cyclohexanone curcumin derivatives in
estrogen receptor negative human breast cancer cell lines. Invest
New Drugs. 29:87–97. 2011. View Article : Google Scholar
|
|
26.
|
Stuart EC and Rosengren RJ: The
combination of raloxifene and epigallocatechin gallate suppresses
growth and induces apoptosis in MDA-MB-231 cells. Life Sci.
82:943–948. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Wang SC and Hung MC: HER2 overexpression
and cancer targeting. Semin Oncol. 28:115–124. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Hsieh WT, Huang KY, Lin HY and Chung JG:
Physalis angulata induced G2/M phase arrest in human breast cancer
cells. Food Chem Toxicol. 44:974–983. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Hsu JD, Kao SH, Ou TT, Chen YJ, Li YJ and
Wang CJ: Gallic acid induces G2/M phase arrest of breast cancer
cell MCF-7 through stabilization of p27(Kip1) attributed to
disruption of p27(Kip1)/Skp2 complex. J Agric Food Chem.
59:1996–2003. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Santen RJ, Song RX, McPherson R, Kumar R,
Adam L, Jeng MH and Yue W: The role of mitogen-activated protein
(MAP) kinase in breast cancer. J Steroid Biochem Mol Biol.
80:239–256. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Wada T and Penninger JM: Mitogen-activated
protein kinases in apoptosis regulation. Oncogene. 23:2838–2849.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Liu B, Han M, Sun RH, Wang JJ, Zhang YP,
Zhang DQ and Wen JK: ABL-N-induced apoptosis in human breast cancer
cells is partially mediated by c-Jun NH2-terminal kinase
activation. Breast Cancer Res. 12:R92010. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Kuo PL, Chen CY and Hsu YL:
Isoobtusilactone a induces cell cycle arrest and apoptosis through
reactive oxygen species/apoptosis signal-regulating kinase 1
signaling pathway in human breast cancer cells. Cancer Res.
67:7406–7420. 2007. View Article : Google Scholar
|
|
34.
|
Collett GP and Campbell FC: Curcumin
induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human
colon cancer cells. Carcinogenesis. 25:2183–2189. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Weir NM, Selvendiran K, Kutala VK, et al:
Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant
human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer
Biol Ther. 6:178–184. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Eto I: Nutritional and chemopreventive
anti-cancer agents up-regulate expression of p27Kip1, a
cyclin-dependent kinase inhibitor, in mouse JB6 epidermal and human
MCF7, MDA-MB-321 and AU565 breast cancer cells. Cancer Cell Int.
6:202006. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Dillon RL, White DE and Muller WJ: The
phosphatidyl inositol 3-kinase signaling network: implications for
human breast cancer. Oncogene. 26:1338–1345. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Burow ME, Weldon CB, Melnik LI, Duong BN,
Collins-Burow BM, Beckman BS and McLachlan JA: PI3-K/AKT regulation
of NF-kappaB signaling events in suppression of TNF-induced
apoptosis. Biochem Biophys Res Commun. 271:342–345. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Gong L, Li Y, Nedeljkovic-Kurepa A and
Sarkar FH: Inactivation of NF-kappaB by genistein is mediated via
Akt signaling pathway in breast cancer cells. Oncogene.
22:4702–4709. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Barkett M and Gilmore TD: Control of
apoptosis by Rel/NF-kappaB transcription factors. Oncogene.
18:6910–6924. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Lauder A, Castellanos A and Weston K:
c-Myb transcription is activated by protein kinase B (PKB)
following interleukin 2 stimulation of T cells and is required for
PKB-mediated protection from apoptosis. Mol Cell Biol.
21:5797–5805. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Shehzad A, Wahid F and Lee YS: Curcumin in
cancer chemoprevention: molecular targets, pharmacokinetics,
bioavailability, and clinical trials. Arch Pharm. 343:489–499.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Dhandapani KM, Mahesh VB and Brann DW:
Curcumin suppresses growth and chemoresistance of human
glioblastoma cells via AP-1 and NFkappaB transcription factors. J
Neurochem. 102:522–538. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Kasinski AL, Du Y, Thomas SL, et al:
Inhibition of IkappaB kinase-nuclear factor-kappaB signaling
pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a
novel monoketone analog of curcumin. Mol Pharmacol. 74:654–661.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Al-Hujaily EM, Mohamed AG, Al-Sharif I, et
al: PAC, a novel curcumin analogue, has anti-breast cancer
properties with higher efficiency on Er-negative cells. Breast
Cancer Res Treat. 128:97–107. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Hutzen B, Friedman L, Sobo M, et al:
Curcumin analogue GO-Y030 inhibits STAT3 activity and cell growth
in breast and pancreatic carcinomas. Int J Oncol. 35:867–872.
2009.PubMed/NCBI
|
|
48.
|
Kumar AP, Garcia GE, Ghosh R, Rajnarayanan
RV, Alworth WL and Slaga TJ: 4-Hydroxy-3-methoxybenzoic acid methyl
ester: a curcumin derivative targets Akt/NF kappa B cell survival
signaling pathway: potential for prostate cancer management.
Neoplasia. 5:255–266. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Lin L, Hutzen B, Ball S, et al: New
curcumin analogues exhibit enhanced growth-suppressive activity and
inhibit AKT and signal transducer and activator of transcription 3
phosphorylation in breast and prostate cancer cells. Cancer Sci.
100:1719–1727. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Anand P, Kunnumakkara AB, Newman RA and
Aggarwal BB: Bioavailability of curcumin: problems and promises.
Mol Pharm. 4:807–818. 2007. View Article : Google Scholar : PubMed/NCBI
|
